NervGen Pharma Stock Forecast for 2023 - 2025 - 2030
Updated on 05/04/2024
NervGen Pharma Stock Forecast and Price Target
In recent months, notable analysts have provided yearlong price targets for NervGen Pharma, with the average target coming in at C$4.50. If it were to be achieved, this would result in a potential upside of approximately 93.13 percent from the most recent closing price in May, 2024. The high end is C$5.00, and the low is C$4.00. If interested in NGEN stock, you may also want to consider its competitors.
93.13% Upside
NervGen Pharma Fair Value Forecast for 2023 - 2025 - 2030
In the last three years, Price for NervGen Pharma has grown by 100.00%, going from C$0.00 to C$0.00. In the coming year, analysts are expecting an increase in Fair Value, predicting it will reach C$2.47 – an increase of 100.00%. Over the next seven years, experts anticipate that Fair Value growth for NervGen Pharma will be 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BHC Stock Forecast | Bausch Health Companies | Hold |
15
|
$7.82 | Buy/Sell | $9.50 | 21.48% |
| TLRY Stock Forecast | Tilray Brands | Outperform |
6
|
$2.10 | Buy/Sell | $2.74 | 4.76% |
| BLU Stock Forecast | BELLUS Health | - |
6
|
C$19.48 | Buy/Sell | C$0.00 | -100.00% |
| CRON Stock Forecast | Cronos Group | Outperform |
6
|
C$3.64 | Buy/Sell | C$3.38 | -7.42% |
| JWEL Stock Forecast | Jamieson Wellness | Outperform |
18
|
C$25.87 | Buy/Sell | C$38.40 | 37.22% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| TSND Stock Forecast | TerrAscend | Buy |
12
|
C$2.40 | Buy/Sell | C$2.74 | 20.00% |
| ACB Stock Forecast | Aurora Cannabis | Outperform |
6
|
C$9.20 | Buy/Sell | C$1.06 | -13.04% |
| GUD Stock Forecast | Knight Therapeutics | Outperform |
14
|
C$5.91 | Buy/Sell | C$6.48 | 18.44% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| OGI Stock Forecast | Organigram Holdings | Outperform |
5
|
C$2.56 | Buy/Sell | C$3.31 | 46.48% |
| FIRE Stock Forecast | The Supreme Cannabis Company | - |
4
|
C$0.33 | Buy/Sell | C$0.00 | -100.00% |
| CPH Stock Forecast | Cipher Pharmaceuticals | Buy |
0
|
C$8.95 | Buy/Sell | C$5.45 | -10.61% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| HITI Stock Forecast | High Tide | Buy |
8
|
C$2.97 | Buy/Sell | C$5.85 | 102.02% |
| BHSC Stock Forecast | BioHarvest Sciences | - |
6
|
C$0.23 | Buy/Sell | C$0.00 | -100.00% |
| HLS Stock Forecast | HLS Therapeutics | Outperform |
15
|
C$4.75 | Buy/Sell | C$6.07 | -24.63% |
NervGen Pharma EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, NervGen Pharma's EBITDA has grown, increasing from C$-11.17M to C$-22.98M – an increase of 105.73%. According to 1 prominent analysts, NervGen Pharma's EBITDA will fall by 31.24% in the next year, reaching C$-15.80M. Over the next seven years, the pros' prediction is EBITDAof C$-26.52M, which would mean a seven-year growth forecast of 15.42%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ONC Stock Forecast | Oncolytics Biotech | Outperform |
0
|
C$1.60 | Buy/Sell | C$7.83 | 353.13% |
| RX Stock Forecast | BioSyent | Outperform |
16
|
C$8.70 | Buy/Sell | C$8.00 | 3.45% |
| TH Stock Forecast | Theratechnologies | Outperform |
8
|
C$1.79 | Buy/Sell | C$8.00 | 237.43% |
NervGen Pharma EBIT Forecast for 2023 - 2025 - 2030
NervGen Pharma's EBIT has increased by 105.63% In the last two years, going from C$-11.20M to C$-23.03M. In the following year, 0 experts forecast NervGen Pharma's EBIT will decrease by 33.78%, to C$-15.25M. In 2030, professionals predict that NervGen Pharma's EBIT will decrease by 27.47%, to C$-16.70M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| VLNS Stock Forecast | The Valens | - |
0
|
C$1.01 | Buy/Sell | C$2.36 | -100.00% |
| LOVE Stock Forecast | Cannara Biotech | - |
-12
|
C$0.93 | Buy/Sell | C$0.00 | -100.00% |
| CXXI Stock Forecast | C21 Investments | - |
0
|
C$0.55 | Buy/Sell | C$0.00 | -100.00% |
NervGen Pharma EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last three years, EPS for NervGen Pharma has grown by 100.00%, going from C$-0.32 to C$0.00. In the coming year, analysts are expecting an increase in EPS, predicting it will reach C$-0.30 – an increase of 100.00%. Over the next seven years, experts anticipate that EPS growth for NervGen Pharma will be 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| HEXO Stock Forecast | HEXO | - |
4
|
C$0.88 | Buy/Sell | C$0.00 | -100.00% |
| DB Stock Forecast | Decibel Cannabis | Buy |
0
|
C$0.12 | Buy/Sell | C$0.50 | 191.67% |
| SOL Stock Forecast | SOL Global Investments | - |
0
|
C$0.10 | Buy/Sell | C$0.00 | -100.00% |
.jpg)